Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Kymera Therapeutics (KYMR) EPS (Basic) (2019 - 2025)

Historic EPS (Basic) for Kymera Therapeutics (KYMR) over the last 7 years, with Q3 2025 value amounting to -$0.94.

  • Kymera Therapeutics' EPS (Basic) fell 1463.41% to -$0.94 in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.6, marking a year-over-year decrease of 5384.62%. This contributed to the annual value of -$2.98 for FY2024, which is 1837.4% down from last year.
  • According to the latest figures from Q3 2025, Kymera Therapeutics' EPS (Basic) is -$0.94, which was down 1463.41% from -$0.95 recorded in Q2 2025.
  • In the past 5 years, Kymera Therapeutics' EPS (Basic) ranged from a high of -$0.25 in Q4 2023 and a low of -$0.95 during Q2 2025
  • Moreover, its 5-year median value for EPS (Basic) was -$0.7 (2023), whereas its average is -$0.69.
  • Per our database at Business Quant, Kymera Therapeutics' EPS (Basic) soared by 9716.52% in 2021 and then tumbled by 27712.28% in 2024.
  • Kymera Therapeutics' EPS (Basic) (Quarter) stood at -$0.67 in 2021, then rose by 11.94% to -$0.59 in 2022, then soared by 57.63% to -$0.25 in 2023, then crashed by 277.12% to -$0.94 in 2024, then increased by 0.3% to -$0.94 in 2025.
  • Its EPS (Basic) stands at -$0.94 for Q3 2025, versus -$0.95 for Q2 2025 and -$0.82 for Q1 2025.